MAR001 successfully lowered triglyceride levels in the phase IIa trial, but whether this reduces CV risk isn’t yet known.
An early stop of the OptimPacing trial may have exaggerated the benefits, but experts say many EPs have already made the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results